I labelled rC5a and fMLP in PMN was determined by radioimmunoassay. The unlabelled chemotaxins were then incubated with PMN and the concentration of calprotectin in PMN lysates and supernatants was measured by an enzyme immunoassay. Results-Both rC5a and fMLP induced release of calprotectin from PMN in a dose dependent manner as determined by a reduction in intracellular calprotectin concentration. A minimum of ∼ 10% of total PMN calprotectin was retained at concentrations of 10-100 nM of rC5a and 0.1-10.0 nM of fMLP. Antibodies to C5a reduced the rC5a mediated release of calprotectin, and the fMLP antagonist N-tBoc-MLP inhibited the fMLP induced calprotectin release. Because receptors for rC5a (CD88) and fMLP are G protein coupled and thought to be pertussis toxin sensitive, PMN were incubated with this toxin before the experiments. The toxin was found to reduce uptake of rC5a by the cells and to inhibit rC5a and fMLP mediated calprotectin release. Conclusions-rC5a and fMLP mediate release of calprotectin from PMN in vitro. This eVect might be important during human infections in vivo. Calprotectin is a calcium binding protein 1 2 found primarily in the cytoplasm of polymorphonuclear neutrophils (PMN) and monocytes. 3 It constitutes ∼ 5.0% of the total protein content of PMN. 1 This 36.5 kDa protein, previously called leucocyte protein L1, was designated calprotectin because it exhibits antimicrobial properties. [4] [5] [6] The plasma concentrations of calprotectin increase during bacterial infections and in chronic inflammatory diseases as a result of its release during activation and turnover of leucocytes. [7] [8] [9] C5a is a potent proinflammatory mediator generated during complement activation. It is formed when C5 is cleaved, to give C5a and C5b. C5b binds to C6-C9 to form the terminal complement complex, which is either inserted as a cytolytic complex into membranes or solubilised by vitronectin/S protein and clusterin (SC5b-9). C5a exerts its anaphylatoxic activities by binding to a specific C5a receptor (CD88) on PMN, 10 monocytes, and nonmyeloid cells. 11 Recently, the C5a receptor has been cloned and characterised. 12 The bacterial chemotaxin formyl-methionine-leucinephenylalanine (fMLP) binds to a specific formyl peptide receptor on myeloid cells and dendritic cells. 13 14 Both the C5a receptor and the fMLP receptor are coupled to a pertussis toxin sensitive G protein. 15 Stimulation of PMN with these ligands triggers a range of biological activities including chemotaxis, superoxide formation, enzyme release, and aggregation. [16] [17] [18] [19] Previously, we found that the plasma concentration of calprotectin increased after plasma apheresis in patients with Waldenström's syndrome, 20 and suspected that this was related to the increase in complement activation products seen in one of these patients. 21 Recently, Garred et al showed that the release of calprotectin coincided with activation of complement during major surgery. 22 The purpose of our study was to examine whether C5a and the bacterial product fMLP, which has similar biological eVects, induce secretion of calprotectin from PMN in vitro.
Materials and methods

PREPARATION OF PMN
The source of PMN was fresh buVy coats (∼ 50 ml) from blood units used to make platelet concentrates at the hospital's blood bank. A volume of 2.5 ml of 20 g/l EDTAK 2 , pH 7.0, was added to each buVy coat. Next, one volume of buVy coat/EDTAK 2 was mixed with four volumes of cold (4°C) isotonic NH 4 Cl containing 10% NaHCO 3 wt/wt, and stored at 4°C for 10 minutes before centrifugation at this temperature at 160 ×g for 10 minutes. The haemolysate was removed and the pellet was resuspended, washed once in isotonic NaCl containing 1 g/l EDTAK 2 , and centrifuged for 15 minutes at 800 ×g through a layer of LymphoprepR (Nycomed, Oslo, Norway). 23 The PMN pellet was washed by centrifugation in a veronal (Diemal) buVer containing 1 g/l EDTAK 2 and usually resuspended to 10 × 10 6 PMN/ml in the same buVer. Typically, the cell preparations consisted of > 96% PMN and contained > 98% live cells (trypan blue exclusion) after a further incubation of one hour. All the buVers were autoclaved and sterile, and endotoxin free tubes and plastic were used to prevent endotoxin contamination. Formyl-N LLPY was used instead of fMLP to enable the peptide to be labelled with iodine. The specific activities of the rC5a and f N LLPY preparations were between 10 and 50 µCi/µg. rC5a and iodine labelled C5a or f N LLPY exhibit biological activities similar to serum derived C5a (Sigma) 24 and fMLP (TE Hugli 1991, personal communication), respectively.
ANALYSIS OF CALPROTECTIN
The calprotectin (L1) concentrations in PMN supernatants were analysed by enzyme immunoassay (EIA). 25 Briefly, the wells (Nunc Immuno Plate; Nunc, Copenhagen, Denmark) were coated with polyclonal rabbit anti-L1 IgG and purified L1 was used as the standard. The binding of PMN L1 was detected by polyclonal alkaline phosphatase conjugated, aYnity purified rabbit anti-L1. The specificity of anti-L1 was determined by double immunodiVusion against L1 purified from leucocytes, 2 by reactivity of anti-L1 in EIA, and by a dot blot against the human plasma gel filtration fraction of 36 kDa corresponding to the molecular mass of calprotectin. 26 This polyclonal antibody reacts with three diVerent epitopes on each of the two types of polypeptide chains of calprotectin as visualised by epitope mapping using synthetic peptides (T Hansen and MK Fagerhol 1996 , unpublished data). The coefficient of variation of this method is ∼ 5% within assays and ∼ 13% between assays. The specificity of this EIA has also been examined by comparison with an EIA using a monoclonal anticalprotectin (MAC 387 clone; DAKO, Glostrup, Denmark) 27 and the two methods were found to be highly positively correlated (MK Fagerhol et al, unpublished data). The normal plasma values of L1 (median ± 2 SD) are 80-880 µg/l (median, 440) for women and 150-910 µg/l (median, 530) for men. Supernatants and lysates of peptide stimulated PMN were also subjected to sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) for examination of calprotectin.
DETERMINATION OF PMN UPTAKE OF PEPTIDES AND SECRETION OF CALPROTECTIN
Cellular uptake of labelled rC5a or f N LLPY was investigated by incubating the peptides for 15 minutes at 37°C with 5 × 10 5 PMN in 100 µl of buVer. The cells were then sedimented, washed, and lysed. Lysis was performed at 0°C by sonication for one minute in 100 µl of a lysis buVer containing 50 mM HEPES, 10 nM EDTA, 2 mM phenylmethyl sulphonylfluoride (PMSF), 0.1 M iodoacetamide, and 15 µg soybean trypsin inhibitor. Radioactivity in the lysis mixture was recorded in a Cobra Autogammacounter (Packard Instruments, Downers Grove, Illinois, USA). The total uptake (binding and internalisation) of labelled rC5a and f N LLPY by the PMN is reported as molecules/cell and the numbers are calculated based on the counts/minute (cpm) values and specific activities of labelled chemotaxins.
To examine whether uptake of C5a could be inhibited by blocking the G protein coupled pathway, PMN, either pretreated or not pretreated with 1 µg/ml of pertussis toxin (Sigma) for 30 minutes at room temperature, were incubated as above, but with unlabelled rC5a. Measurement of C5a in cell lysates was performed in a sandwich EIA based on monoclonal antibodies to a neoepitope on C5a/C5a desArg, which is concealed in native C5a but exposed in the activated fragment. 28 29 For examination of PMN calprotectin release, rC5a (1-100 nM) and fMLP (0.1-100.0 nM) (F 3506; Sigma) were incubated with 1-5 × 10 6 PMN in 1 ml conical Nunc cryotubes (Nunc) containing veronal buVer with EDTAK 2 at 37°C in a volume of 100 µl. The PMN were incubated for 20 minutes to ensure that the plateau for chemotaxin uptake after 15 minutes was reached. Controls were cells incubated with buVer alone, or cells pretreated either with 1 µg/ml of pertussis toxin (P 9452; Sigma), 10 nM of the fMLP antagonist N-t-Boc-MLP (B 0511; Sigma), 30 or with 10 mg/ml of human globulin for 30 minutes at room temperature to block Fc receptors before addition of polyclonal antibodies to C5a (12.5% vol/vol from Amersham's C5a/C5a desArg radioimmunoassay kit) together with C5a. The cells were pelleted and the supernatant removed and stored at −20°C until the concentration of calprotectin was measured. Results from inhibition experiments performed with diVerent concentrations of C5a or fMLP are presented together. The pellets were lysed and frozen immediately. The concentration of 
(5) (6) 1000 100 10 1 (2) calprotectin in PMN lysates or supernatants was measured as µg/l and reported as a percentage of the measured total calprotectin content in lysates plus supernatants of unstimulated PMN (mean and range values, 2.2 and 1.3-3.6 pg/cell, respectively, which are similar to values published previously). 1 
CONTROLS
To exclude the possibility that endotoxin was responsible for the observed release of calprotectin from PMN, random samples of both the buVers, cell lysates, and supernatants were examined for endotoxin content using a limulus amoebocyte lysate 31 EIA kit (Chromogenix, Mölndal, Sweden). In some experiments, polymyxin B (P 1004; Sigma), which inactivates endotoxin, 32 was also added to the cell preparations, but no reduction in background secretion of calprotectin was seen. In other experiments, equal volumes (5 ml) of untreated buVy coats were either enriched or not enriched with PMN isolated from 5 ml of the same buVy coats, and incubated at 37°C and 4°C for one, four, or 24 hours and the concentration of calprotectin measured in the plasma supernatants. PMN were also incubated with 10 mM Ca 2+ , for possible reduction of background by stabilisation of the cells, or with 30 mM PMSF, to reduce proteolysis of calprotectin, but no eVects were seen (data not shown).
STATISTICS
The 1) . The uptake of rC5a 24 and f N LLPY (data not shown) by PMN reaches a plateau after 15 minutes of incubation, the incubation time used here. Uptake of unlabelled rC5a by PMN pretreated or not pretreated with pertussis toxin (1 µg/ml) was assessed by a C5a/C5a desArg EIA. Uptake was dose dependent and was reduced by pertussis toxin (p = 0.0357; Wilcoxon signed rank test of all data points) (fig 2) .
Results
UPTAKE
EFFECT OF rC5a AND fMLF STIMULATION ON SECRETION OF CALPROTECTIN BY PMN
The concentration of calprotectin in lysates and supernatants of PMN incubated with 0-200 nM of rC5a for 20 minutes was examined. rC5a had a dose dependent bimodal stimulatory eVect on the release of calprotectin from PMN, as determined by reduction in intracellular calprotectin (fig 3) . A minimum of 10% of total PMN calprotectin was retained at an rC5a concentration of 100 nM, which was significantly lower than the amount retained by the control (no rC5a) (p < 0.0425; Wilcoxon signed rank test). PMN stimulated with 0-100 nM fMLP also released calprotectin in a dose dependent bimodal manner (fig 3) . Similar minimal values (11-12%) of total PMN calprotectin to those observed with C5a stimulation were retained at the three middle fMLP concentrations (p < 0.0431 compared with control), suggesting that all cell associated calprotectin is released. Thus, C5a and fLMP induced a reduction in the total PMN calprotectin concentration of ∼ 60% and 70%, respectively, compared with unstimulated control cells.
When calprotectin was measured in PMN supernatents, little or no dose response was seen in rC5a or fMLP stimulated cells PMN (data not shown). This is because such stimulation also mediates the release of proteolytic enzymes that digest calprotectin.
REDUCTION OF rC5a AND fMLP MEDIATED RETENTION OF CALPROTECTIN BY TREATMENT OF PMN WITH PERTUSSIS TOXIN, ANTIBODIES, OR
ANTAGONIST
To investigate whether the chemotaxin induced PMN secretion of calprotectin is medited by a G protein coupled mechanism, PMN were incubated with pertussis toxin before addition of rC5a (1-200 nM) or fMLP (0.1-100.0 nM). Figure 4 shows that the secretion of calprotectin from PMN mediated by C5a or fMLP was inhibited significantly; inhibition was ∼ 50% (p = 0.0329) and ∼ 45% (p = 0.0047; Wilcoxon one sample test of all data points), respectively. When rC5a was added after pre-incubation of PMN with polyclonal anti-C5a, there was a small (30%), but significant reduction (p = 0.0357; Wilcoxon one-sample test of all data points) in the release of calprotectin.
In experiments with fMLP stimulation, pretreatment of cells with the fMLP antagonist N-t-Boc-MLP reduced the calprotectin secretion by ∼ 40% (p = 0.0437; Wilcoxon one sample test) (fig 4) .
DETERMINATION OF CAUSE OF BACKGROUND RELEASE OF CALPROTECTIN
BuVy coat samples were incubated at diVerent temperatures and intervals without mediators, and calprotectin was measured in the supernatants. Table 1 shows that a high concentration of calprotectin, which reached a plateau after four hours, was detected in buVy coat supernatants incubated at 37°C. An additional 24 hour incubation at 4°C after an initial one hour incubation at 37°C did not influence the release of calprotectin. The release of calprotectin increased twofold when buVy coats were supplemented with PMN isolated from an equal volume of the same buVy coat, showing that PMN were responsible for the release and that the isolation of PMN per se was not a major background variable. In contrast to the finding with buVy coats alone, prolonged incubation of buVy coats plus PMN for 24 hours resulted in reduced calprotectin concentrations compared with the four hour value. This suggests that a time, temperature, and PMN dependent mechanism induced breakdown of calprotectin in the supernatants.
Discussion
Our results show that the endogenous C5a and exogenous formyl peptide chemotaxins are taken up by PMN and promote in vitro release of calprotectin from PMN at or above the ED 50 (median eVective dose) of the ligands (2-10 nM). 33 34 The indicated bimodal dose dependency curves (fig 3) for calprotectin release correspond with the reported bimodal curve for monocyte production of interleukin 8 (IL-8) after C5a stimulation, and might indicate a self-regulatory mechanism or desensitisation of the cells at high concentrations of the stimulator. 10 35 Our findings also indicate that the C5a and fMLP induced PMN secretion of calprotectin occurs via a G protein coupled pathway, which is one proposed mechanism for the eVects of C5a, fMLP, and other chemotactic ligands (IL-8, leukotriene B4) upon binding to their receptors in the rhodopsin receptor family. 15 However, it has been suggested that a subpopulation of fMLP receptors on myeloid cells are maintained in a low aYnity G protein free state and are therefore pertussis insensitive. 34 Because C5a binds to a similar receptor to fMLP and has similar eVects on PMN, C5a might also stimulate PMN via pertussis toxin sensitive and insensitive pathways. This might account for the incomplete inhibition in C5a and fLMP uptake and calprotectin release seen after peptide stimulation of pertussis toxin treated cells.
There was a high background release of calprotectin into the supernatant from unstimulated PMN. Because endotoxin is a known inducer of PMN enzyme release, 36 and stimulates calprotectin secretion from monocytes (Lyberg et al, unpublished data), it might also induce release of calprotectin from PMN. The experiments were performed under sterile conditions and rigorous eVorts were made to exclude endotoxin contamination. Endotoxin was not detected in random samples, indicating that factors other than endotoxin were responsible for the background release of calprotectin. Because PMN are fragile and easily stimulated in vitro, as shown by their tendency to aggregate, handling of the cells during isolation might trigger some calprotectin release, but eVorts to stabilise the cells did not reduce the leakage. However, experiments with unstimulated buVy coats indicated that the incubation temperature of 37°C was the parameter responsible for most of the background release of calprotectin in vitro. We chose this temperature in our experiments because it has been useful in C5a stimulation studies previously. 14 24 In contrast with calprotectin in buVy coats alone, the concentrations of calprotectin in buVy coats incubated with PMN overnight at 37°C, but otherwise untreated, were reduced to the one hour value. Because there is a normal time and temperature dependent activation of complement in stored plasma, 37 the observed calprotectin reduction is probably a result of C5a formation and induction of PMN release of proteolytic enzymes, which might digest the secreted calprotectin.
Isolated calprotectin is digested by lysosomal enzymes from PMN at 37°C in the absence of enzyme inhibitors. 26 Therefore, calprotectin is probably better protected intracellularly than extracellularly after release induced by C5a and fMLP, which also mediate release of lysozymes. Because of the calprotectin degradation by proteolytic enzymes, we used the remaining cellular calprotectin concentration to estimate the amount of protein released after peptide stimulation. The determined PMN associated calprotectin in lysates, like the measured cell associated C5a (fig 2) , 28 comprises both intracellular and membrane bound protein.
Using the same polyclonal anti-L1 antibody that we used, Dale and colleagues 3 demonstrated immunofluorescent staining of calprotectin both in the cytoplasm and on the plasma membrane of PMN along with lysozyme. Moreover, in activated monocytes, L1 subunits are shown to associate with the membrane and cytoskeleton in a Ca 2+ dependent manner. 38 In fact, the observed 10% minimal retention of total calprotectin in lysates of PMN stimulated with the most eVective C5a and fMLP doses suggests that some calprotectin is located in the cell membranes during exocytosis of the protein.
In addition to proteolytic lysozymes, activated PMN release other antimicrobial factors like oxygen radicals and defensins. However, the importance of calprotectin release relative to other antimicrobials in vivo was demonstrated by Santhanagopalan and colleagues, 39 who found calprotectin to be responsible for most of the anti-Candida albicans activity of empyema fluid supernatants. Previously, abscess fluid supernatants have been found to inhibit microbial growth, an eVect that appeared to be a result of PMN cytoplasmic calprotectin. 40 The fact that crude empyema fluid contains 25-50% PMN by volume 39 suggests the importance of chemotaxins for PMN recruitment and subsequent calprotectin secretion. In septicaemia, another condition that induces C5a and fMLP formation, the plasma concentrations of calprotectin are reportedly over threefold higher than in healthy individuals. 1 To estimate the proportion of the increase in in vivo calprotectin concentrations that C5a and fMLP might contribute to, one could compare our in vitro findings with the normal plasma concentration of calprotectin (0.5 mg/l) and adjust the figures for the 10 fold higher PMN concentration used in vitro. A brief calculation of the maximal net PMN calprotectin concentration released by C5a and fMLP in vitro (15% and 30% of total 10 µg/5 × 10 6 PMN) (fig 3) gives threefold and sixfold, respectively, higher calprotectin concentrations than is normally found in vivo.
During invasion with microorganisms, complement activation and subsequent C5a generation is one of the host's defense mechanisms. Because C5a recruits PMN and monocytes to the infection focus and calprotectin is shown to possess antimicrobial activities, 4-6 secretion of calprotectin from C5a stimulated PMN might be biologically useful. The dose response experiments show that the antimicrobial agent can be secreted from intact live PMN and not just released from dead and disintegrated cells. Formyl peptides are bacterial products. The proposed ability of fMLP to induce secretion of calprotectin from PMN supplements the role of C5a during infection. Bacteria killed by calprotectin might release additional fMLP, which again would promote secretion of more calprotectin from a higher number of newly recruited PMN and thus give rise to a positive feedback loop. Bacterial endotoxin could induce a similar calprotectin driven antimicrobial eVect that acts additively with the fMLP induced eVect.
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